Talquetamab Plus Daratumumab Earns CHMP Backing in R/R Myeloma
The EMA's CHMP recommended expanding talquetamab (Talvey) to include its use with daratumumab (Darzalex) in relapsed/refractory multiple myeloma. The phase 3 MonumenTAL-3 trial showed a 72% risk reduction in progression or death for talquetamab plus daratumumab and pomalidomide (Tal-DP) vs standard therapy. Johnson & Johnson's Ester in 't Groen highlighted significant improvements in PFS and OS, according to the company.
How this was made
The 30-second read
Why it matters
MonumenTAL-3 interim results showed large PFS risk reductions versus DPd, with OS also favoring both talquetamab arms, supporting the regulatory rationale for earlier-line combination use.
Market read
This is a material EU regulatory milestone for a marketed oncology product, driven by phase 3 efficacy and OS signals in a combination setting.
What to watch
Safety remains heavy (high grade 3/4 TEAEs and infection rates), and real-world adoption will depend on tolerability, logistics of subcutaneous dosing, and competitive positioning versus other myeloma regimens.
Background
The CHMP recommended expanding talquetamab (Talvey) to a combination regimen with daratumumab (Darzalex), with or without pomalidomide (Pomalyst), for adults with relapsed/refractory multiple myeloma after at least one prior therapy line.
Ticker impact
CHMP recommended expanding Johnson & Johnson’s Talvey (talquetamab) to be used with daratumumab, with or without pomalidomide, in relapsed/refractory multiple myeloma.
Likely positive bias as investors price in higher future sales optionality and reduced regulatory risk for the combination label.
The article reports a CHMP positive opinion for an expanded indication based on MonumenTAL-3 efficacy and OS/PFS benefits, which is a material regulatory milestone for the product and its commercial outlook.
Market effects
Reinforces momentum for bispecific and combination regimens in relapsed/refractory multiple myeloma, potentially lifting sentiment across myeloma-focused biotech/pharma.
Supports EU commercialization prospects for the Talvey combination, which can influence European myeloma treatment expectations.
May strengthen global payer and guideline discussions for talquetamab-based combinations, even outside Europe.
Counterpoint
A CHMP recommendation is not the final EMA approval, so near-term pricing may overreact versus the probability/timing of final label expansion.
Key entities
- companyJNJ
Johnson & Johnson, sponsor/portfolio owner of Talvey, cited in the article’s trial and CHMP context.
- drugTalvey (talquetamab)
GPRC5D-targeting therapy whose indication expansion is recommended by CHMP.
- drugDarzalex (daratumumab)
CD38-targeting therapy combined with talquetamab in the recommended regimen.
- clinical_trialMonumenTAL-3
Phase 3 trial providing the efficacy and safety evidence for the CHMP recommendation.
- regulatorCHMP
EMA committee issuing the positive opinion for the expanded indication.
